| Assessment Status | Rapid Review Complete |
| HTA ID | 21014 |
| Drug | Nivolumab plus ipilimumab plus platinum-doublet chemotherapy |
| Brand | Opdivo® plus Yervoy® |
| Indication | For the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation. |
| Assessment Process | |
| Rapid review commissioned | 31/03/2021 |
| Rapid review completed | 30/04/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that nivolumab in combination with ipilimumab plus platinum-doublet chemotherapy not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations March 2022.
